PATENT CLAIM ANALYSIS

Application Number: 16119263
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "263220"]

Abstract:
The invention discloses compositions comprising BRaf inhibitors and uses thereof for treating and/or preventing by topical or systemic administration cutaneous conditions caused by treatment with EGFR inhibitors and/or PI3K inhibitors.

Claim (Index 4):
The method of  claim 1 , wherein the BRaf inhibitor is selected from: BAY43-9006 (Sorafenib), LGX818 (encorafenib), PLX4032 (vemurafenib), GSK2118436 (dabrafenib), ARQ197 (Tivatinib), GSK1120212 (trametinib), ARQ736, ARQ680, AZ628, CEP-32496, GDC-0879, C-1, C-15, C-19, C-A, NMS-P186, NMS-P349, NMS-P383, NMS-P396, NMS-P730, PLX3603 (RO5212054), PLX4720 (Difluorophenyl-sulfonamine), PF-04880594, PLX4734, RAF265, RO4987655, SB590885, BMS908662, WYE-130600, TAK632, MLN 2480, XL281 and combinations thereof.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 1.14815
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15002457', '12865620', '14147689', '14770994', '15105904']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7638530932724309
- 35 USC 102 Novelty (BERT): 0.5250096333122164
- Combined Prediction Score: 0.7399687472764095
- Mean Citation Score: 302.35572
- Max Citation Score: 316.7195700000001
- Similarity Product: 248.03838925179008

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test